A raised PSA result opens a question rather than answering it. The blood test can help identify prostate problems, but an abnormal reading does not establish cancer. For adults thinking about healthy ageing, the useful issue is what follows the result: confirmation, assessment, and sometimes MRI or biopsy. The US National Library of Medicine explanation of PSA testing describes that sequence.
The screening evidence needs an absolute number
In a 2024 analysis of the CAP trial in JAMA, Richard Martin and colleagues reported prostate cancer mortality after a median 15 years. Men aged 50–69 had been allocated through their GP practices to a single invitation for PSA screening or usual care without that invitation.
The estimated risk of dying from prostate cancer was 0.69% in the invitation group and 0.78% in the control group. The absolute difference was 0.09 percentage points: roughly nine fewer prostate cancer deaths per 10,000 men invited. Screening also increased detection of low-grade disease. These are results of an invitation policy, not a guarantee for an individual who takes a test.
The follow-up was a secondary analysis, and few Black men were included. The trial began before today’s diagnostic approaches. It therefore gives useful evidence about one screening strategy, rather than settling every question about present-day screening.
For a reader, the denominator matters. A relative reduction without the underlying risks leaves too much room for the imagination. Both the possible benefit and the uncertainty belong in the conversation.
PSA is a signal with several possible explanations
PSA stands for prostate-specific antigen. A result above a laboratory’s reference range is information to interpret, not a tissue diagnosis. The US National Cancer Institute’s PSA fact sheet explains that there is no single level which separates cancer from its absence.
Inflammation, infection, and recent procedures can raise the result. Finasteride and dutasteride, medicines used for benign prostate enlargement, can lower it. The medication list therefore belongs alongside the measurement. A low reading without that context may be misleading. MedlinePlus advises against stopping medicines unless the treating clinician says to do so.
The National Cancer Institute distinguishes false positives from overdiagnosis. A false positive means a raised test without cancer. Overdiagnosis means finding a cancer that would not have caused problems during the person’s lifetime. They are different harms: one can lead to unnecessary investigation, the other to unnecessary treatment.
The National Cancer Institute describes the harms of investigation and treatment: biopsy can cause pain, bleeding, and serious infection, whilst treatment can affect urinary, bowel, and sexual function. This is why finding more cancers is an incomplete measure of success. The question should always be whether the testing pathway improves outcomes enough to justify its harms.
A repeat test needs a reason and a follow-up plan
A second measurement can help establish whether an elevation persists. The MedlinePlus explanation of test results describes repeat measurement amongst the options for investigating a high result, particularly without symptoms.
The NHS PSA test page describes preparation that can affect interpretation: ejaculation, cycling, anal sex, and exercise that leaves someone out of breath should be avoided for 48 hours before the test. After a urine infection, the guidance describes waiting four to six weeks after it has cleared. Confirm preparation and timing with the treating service. These are considerations for a properly arranged test, rather than reasons to cancel or postpone an assessment independently.
The useful discussion is why a repeat is being proposed, when it will happen, and who will review it. A repeat requested because of a possible temporary influence is different from indefinite reassurance without a plan. Readers can ask for that distinction to be explained.
A number in an app can be easy to retrieve. The explanation attached to it deserves just as much attention. Recording the date and the clinician’s follow-up plan is more useful than trying to manufacture a better-looking result.
MRI changed the pathway, not the meaning of certainty
Veeru Kasivisvanathan and colleagues tested an MRI-based diagnostic strategy in the 2018 PRECISION trial in The New England Journal of Medicine. The 500 participants had clinical suspicion of prostate cancer and had not previously undergone biopsy.
Clinically significant cancer was detected in 38% of the MRI-strategy group and 26% of the standard-biopsy group. In the MRI group, 28% had a scan that was not suggestive of cancer and avoided biopsy. The strategy also detected fewer clinically insignificant cancers. That is evidence for improving diagnosis in a selected clinical population. It is not evidence that anyone with a prostate should book an MRI, or that this trial demonstrated fewer deaths.
NICE guidance on prostate cancer diagnosis places multiparametric MRI early in assessment for suspected clinically localised disease. It advises against automatically offering biopsy on PSA alone. Examination findings, other illnesses, risk factors, and previous biopsy results help shape the decision.
A low-risk MRI can support a shared decision to omit biopsy, but it does not eliminate the possibility of significant cancer. The remaining uncertainty, and the follow-up needed to address it, should be explained before that decision is made.
Targeting a visible area can still miss other disease
The next question is what tissue should be sampled if biopsy is needed. An MRI-targeted biopsy takes samples from suspicious areas identified on the scan. Systematic biopsy samples other areas according to a planned pattern.
In a 2020 study in The New England Journal of Medicine, Michael Ahdoot and colleagues evaluated both approaches in 2,103 men with MRI-visible lesions. The combined approach detected cancers that either method alone would have missed. Among the subgroup who later underwent surgery, combined biopsy also produced fewer upgrades to grade group 3 or higher when the removed prostate was examined.
This was a selected diagnostic cohort, not a trial of population screening. The surgery subgroup was more selected still. Its findings cannot establish a universal biopsy prescription, but they illustrate why an apparently precise target is not the whole diagnostic problem.
For readers, the practical question is what the proposed biopsy approach is intended to resolve, and what uncertainty would remain afterwards. A scan, a tissue sample, and a long-term outcome are distinct pieces of evidence. None should borrow the certainty of the others.
Symptoms belong in a separate conversation
Choosing screening when well is different from investigating a symptom. The NHS guidance on prostate cancer symptoms notes that early prostate cancer often causes no symptoms. Trouble passing urine, changes in urinary flow or frequency, and blood in urine or semen are amongst the changes that merit medical assessment.
These symptoms can also have non-cancerous explanations, including benign prostate enlargement. Their presence is not a diagnosis. Their absence is not proof that screening will be useful, either.
The NHS advises seeing a GP for symptoms that change, worsen, or do not feel normal, and for concerns about personal risk. That remains a useful boundary after a reassuring test result: new symptoms deserve a clinical conversation rather than being explained away by an earlier number.
Risk discussions can include family history and known inherited variants, as explained in the National Cancer Institute discussion of higher-risk groups. Someone who already has a prostate cancer diagnosis or is receiving treatment needs advice for that situation; screening evidence should not be used to reinterpret a specialist monitoring plan.
What this means in practice
- Before requesting screening, ask what benefit is plausible for your circumstances and which harms matter to you. Bring questions rather than a predetermined testing schedule.
- If a test is arranged, confirm preparation with the service and mention recent infection, procedures, and medicines. The NHS test page sets out common preparation issues.
- After a raised result, ask who will review it, whether a repeat or referral is proposed, and when you should expect contact.
- If MRI or biopsy is discussed, ask what it may find, what it may miss, and how each possible result would change care. These are central to NICE’s shared decision approach.
- Arrange assessment for changing urinary symptoms rather than relying on a previous result, as described in NHS symptom guidance.
What we don’t know
These studies answer different questions. CAP assessed a single screening invitation over years; PRECISION assessed diagnostic detection; Ahdoot’s cohort compared sampling methods. Combining their findings does not create a trial proving that a particular modern PSA–MRI–biopsy sequence will extend every individual’s life.
Better detection and fewer unnecessary diagnoses are worthwhile aims. Establishing the balance of benefits and harms across different risk groups still requires outcome evidence. The individual decision also depends on the clinical circumstances and preferences that a population average cannot supply.
PSA is most useful when its limitations travel with the result. A careful testing decision includes an explanation, a next step, and room for uncertainty.
Photo: Louis Reed on Unsplash. Laboratory illustration; not a photograph of a PSA assay.
